Biologics/Immunotherapy News

A dose of omalizumab administered before pollen season improved symptom control and quality of life compared with standard medication among patients with seasonal allergic rhinitis, according to a study in Clinical and Translational Allergy.

Omalizumab benefited patients with moderate to severe allergic asthma regardless of their BMI, according to a study published in Annals of Allergy, Asthma & Immunology.

Cancer cell-derived or allergic reaction-released histamine dampened antitumor immunity and conferred resistance to cancer immunotherapy, according to a retrospective study published in Cancer Cell.

Mepolizumab reduced polyp size and nasal obstructions in patients with chronic rhinosinusitis with nasal polyps regardless of comorbid asthma or aspirin-exacerbated respiratory disease, according to data from an exploratory analysis.

Oral immunotherapy has shown promise in inducing remission of specific food allergies, with one FDA-approved option available for peanut allergy, but these patients often shoulder the burden of multiple food allergies.

Adults with moderate-to-severe atopic dermatitis treated with dupilumab had fewer and shorter hospitalizations related to the skin condition, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Most patients with severe cow’s milk allergy can be safely desensitized to substantial levels of baked milk through baked milk oral immunotherapy, according to a study published in The Journal of Allergy and Clinical Immunology.

A panel of experts has compiled 10 tips to help physicians, patients and their families optimize the use of the oral immunotherapy Palforzia — the first FDA-approved treatment for peanut allergy in children aged 4 to 17 years.

Dupilumab and benralizumab both improved sense of smell in patients with chronic rhinosinusitis with nasal polyps, and benralizumab also decreased nasal blockage, according to results of two studies.

Risankizumab appeared to worsen severe asthma symptoms compared with placebo, according to results of a randomized phase 2a study published in The New England Journal of Medicine.